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Introduction
The complexity of  kidney structure and function make understanding the mechanisms responsible for 
kidney disease development and progression challenging. Genome-wide bulk mRNA profiles of  kidney 
tissues provide a starting point to map the molecular underpinning of  disease pathogenesis and progres-
sion. Successes of  this approach include the identification of  noninvasive biomarkers from tissue gene 
expression studies of  acute kidney injury (1), chronic kidney disease (2), and targets for potentially novel 
therapeutic approaches (3, 4). However, bulk mRNA gene expression measurements reflect an average 
across all captured cell types rather than focusing on cell-specific transcriptional responses. Analytical 
approaches to identify the most likely cellular source of  transcriptional profiles have been used to over-
come this limitation (5–7). While these methods have improved our understanding of  cellular contribu-
tion to bulk mRNA expression profiles, they do not fully capture the transcriptional programs of  individ-
ual cells. In recent years, RNA sequencing approaches at the single cell transcriptome level (scRNAseq) 
have been developed and are being refined specifically for kidney tissue (8, 9). scRNAseq allows the mea-
surement and comparison of  comprehensive gene sets obtained from individual cells and, thus, enables 
the capture of  previously underappreciated cellular heterogeneity within kidney tissue in health and dis-
ease. For example, scRNAseq studies (10–14) have provided comprehensive and dynamic gene expression 
profiles of  the human developing kidney and human organoids at the single cell level (10, 12) and have 
identified resident immune phenotypes in kidney tissues in lupus nephritis (15).
To define cellular mechanisms underlying kidney function and failure, the KPMP analyzes biopsy 
tissue in a multicenter research network to build cell-level process maps of the kidney. This study 
aimed to establish a single cell RNA sequencing strategy to use cell-level transcriptional profiles 
from kidney biopsies in KPMP to define molecular subtypes in glomerular diseases. Using multiple 
sources of adult human kidney reference tissue samples, 22,268 single cell profiles passed 
KPMP quality control parameters. Unbiased clustering resulted in 31 distinct cell clusters that 
were linked to kidney and immune cell types using specific cell markers. Focusing on endothelial 
cell phenotypes, in silico and in situ hybridization methods assigned 3 discrete endothelial cell 
clusters to distinct renal vascular beds. Transcripts defining glomerular endothelial cells (GEC) were 
evaluated in biopsies from patients with 10 different glomerular diseases in the NEPTUNE and 
European Renal cDNA Bank (ERCB) cohort studies. Highest GEC scores were observed in patients 
with focal segmental glomerulosclerosis (FSGS). Molecular endothelial signatures suggested 2 
distinct FSGS patient subgroups with α-2 macroglobulin (A2M) as a key downstream mediator of 
the endothelial cell phenotype. Finally, glomerular A2M transcript levels associated with lower 
proteinuria remission rates, linking endothelial function with long-term outcome in FSGS.
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The KPMP has been created with a goal to change the way we understand and treat kidney disease. KPMP 
has identified access to human biopsy tissue as a critical first step in defining disease heterogeneity and deter-
mining the precise molecular pathways driving kidney disease. Tissue from a kidney biopsy can provide the 
opportunity for a variety of  molecular analyses of  diseases embedded in both the structural organ context and 
the clinical phenotype (16). Despite collaborative success in collecting biopsy tissue, generating single cell data 
from adult human nephrons, with their highly differentiated epithelial and endothelial subtypes, has proven 
particularly challenging due to the rapid decline in cell viability upon dissociation (17). Recently, first cell/
nucleus analyses of  normal adult human kidneys have been published (9, 18, 19). However, a comprehensive 
map of  single cell types from multiple normal human kidney sources such as nontumor sections of  tumor- 
nephrectomies, surveillance, and preperfusion biopsies is yet to be developed. Such a reference map for the 
adult human kidney will provide insights into human disease and is critical as a comparator for biopsy-driv-
en single cell studies aiming to identify underlying targetable mechanisms for early detection and treatment.
An overall strategy was developed to address 3 main goals presented in this study: (a) to establish a protocol for 
kidney biopsy–based scRNAseq analysis capturing all cellular elements of the kidney (Figure 1); (b) to establish a 
map of the transcripts found in kidney cell types defined by data-driven clustering; and (c) to test the ability of this 
technique to identify distinct, cell type–specific features seen in bulk RNA profiling from human kidney disease as 
a means to understand and identify key cellular mechanisms underlying kidney disease phenotypes (Figure 2).
Results
KPMP scRNAseq protocol for analysis of  adult human kidney. Intrinsic nephron cell types and tissue-resident 
immune cells were recovered from kidney biopsy specimens using a scRNAseq protocol for KPMP, designed 
Figure 1. Analysis workflow showing the generation of adult kidney single cell clusters. Combined processing of 24 samples including 16 tumor-nephrectomy, 5 
surveillance, and 3 preperfusion biopsies using the scRNAseq protocol yielded 22,268 cells (4690 from surveillance biopsies; 14,744 from tumor-nephrectomies; 
and 2834 cells from preperfusion biopsies) and resulted in 31 distinct clusters. Seurat R package was used for the unsupervised clustering of the single cell data.
 
3insight.jci.org   https://doi.org/10.1172/jci.insight.133267
R E S E A R C H  A R T I C L E
for deployment in a multicenter research network (kpmp.org). Twenty-four adult, nondiseased, human kid-
ney tissue samples were processed using the KPMP scRNAseq protocol, including 16 unaffected specimens 
from tumor-nephrectomies, 3 preperfusion living donor kidney biopsies, and 5 surveillance kidney trans-
plant biopsies. The combined samples yielded 22,268 cells (4690 from surveillance biopsies, 14,744 from 
tumor-nephrectomies, and 2834 cells from preperfusion biopsies) that passed the KPMP quality control 
parameters. Unsupervised clustering of  all 22,268 cells resulted in 31 distinct clusters, ranging in size from 
1412 cells to 58 cells (Figure 3A and Table 1). The scRNAseq expression data set has been loaded into the 
scRNAseq viewer Nephrocell and can be explored at Nephrocell.MiKTMC.org.
Identification of  kidney cell types. Differential expression analysis of the genes expressed in each cluster ver-
sus all other clusters generated cell type–specific gene sets (FDR < 0.05) (Supplemental Table 1; supplemen-
tal material available online with this article; https://doi.org/10.1172/jci.insight.133267DS1). Each gene set 
included known kidney cell type–specific markers, which enabled assignment of clusters to specific cell types. 
Once cluster identities were established, the gene sets provided potentially novel cell type–specific markers. 
Figure 3B indicates the cluster (or cell type) specificity of the most differentially expressed genes in each cluster.
Each cluster included cells from all 3 different sample sources used, supporting comparable cellular 
yields from each source and the absence of  sample-specific batch effects (Figure 4). Distribution of  cells 
from all 24 samples in the 31 clusters are listed in Supplemental Table 2. Alignment of  cell clusters with 
kidney cell types (20) using known cell type markers are outlined in Supplemental Table 1.
Proximal tubule (PT) cells populated the most abundant clusters (clusters 10–16, Figure 3A). Cells from at 
least 21 out of the 24 samples were found across 7 PT clusters, confirming broad contribution to the cellular clus-
ters by the diverse samples (Supplemental Table 2). The top markers for cluster 10–16 were mitochondrial genes 
(Figure 3B and Supplemental Table 1), suggestive of gradient differences in mitochondrial gene expression in 
these 7 clusters (Supplemental Figure 1A). Increased mitochondrial activity in the PTs is well known (21). More-
over, single nucleus RNAseq (snRNAseq) studies, including those from KPMP on identical tumor-nephrectomy 
tissues, have also reported more than the conventional PT cell types (S1, S2, and S3 cells) in their analyses (18, 19).
Figure 2. Analysis workflow showing the integration of single cell with bulk mRNAseq data. The glomerular endothelial-specific transcripts identified 
from scRNAseq analyses were used to identify distinct subgroups within FSGS using mRNAseq profiles available from NEPTUNE.
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The cells of the distal nephron constituted the next-largest clusters, were identified based on known markers, 
and included descending thin limb (DTL, cluster 31), ascending thin limb (ATL, cluster 29), thick ascending limb 
(TAL, cluster 20) of the loop of Henle (LOH), distal convoluted tubule (DCT, cluster 21), connecting tubule 
(CNT, cluster 22), and collecting duct cells (principal cells [PC], cluster 27; and intercalated cells [IC] A and B, 
clusters 17 and 18, respectively). The Uniform Manifold Approximation and Projection (UMAP) dimensionality 
reduction process of the expression data preserved the global structure (22) of the distal nephron (Figure 3A). In 
addition to the major distal nephron cell types, we identified 3 cell clusters (clusters 19, 28, and 30) for which the 
top differentially expressed genes suggested that the clusters consisted of potentially transitioning cell types.
The top differentially expressed genes in cluster 19 included known markers from principal (FXYD4) 
and intercalated (ICA [SLC26A7] and ICB [SLC4A9]) collecting duct cells (Figure 5A). A similar cell 
Figure 3. Unsupervised clustering of cells derived from adult kidney tissue. (A) UMAP plot from unsupervised clustering of 22,268 cells and number of 
cells in each of the 31 clusters. (B) Expression levels of the top differentially expressed gene from each cluster across all clusters. Differential gene expres-
sion analyses, to identify cell type specific genes, were performed using the nonparametric Wilcoxon rank sum test. The cell type–specific genes with FDR 
< 0.05 were considered as differentially expressed. UMAP, Uniform Manifold Approximation and Projection.
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cluster was previously reported and validated by a scRNAseq study in mice (14). This cluster had a 
comparatively higher mRNA content (Supplemental Figure 1B).
Cluster 28, which we annotated to contain CNT-PC (cortical CNT IC) expressed known markers of  
both PCs (FXYD4, STC1) and CNT cells (SLC8A1) (Supplemental Figure 1C), consistent with transitional 
states between CNT to cortical collecting duct cells.
The cell type markers of  cluster 30 included CTGF, CRB2, VCAM1, SLC4A11, and CLDN1 (Sup-
plemental Table 1). Antibody staining of  the coded proteins of  those top genes referring to the 
Human Protein Atlas (HPA; https://www.proteinatlas.org), showed that most of  these markers were 
expressed in glomerular parietal epithelial cells (PEC) and LOH cells. On examining this cluster 
more closely, subclustering showed 2 clusters, subcluster 0 and 1, contained within cluster 30 (Fig-
ure 5B). The expression of  WT1, CLDN1, and CRB2 in subcluster 0 suggests that this subcluster was 
enriched for PEC, while the expression of  TACSTD2 and SPP1 in subcluster 1 indicates enrichment 
for LOH-derived cells.
Cluster 2 contains cells with known podocyte-specific markers, allowing the identification of  potential-
ly novel podocyte-specific transcripts (Figure 5C). Cluster 2 is composed of  170 cells identified as podo-
cytes based on expression of  known, podocyte-specific markers NPHS1, NPHS2, and PODXL. Podocytes 
were identified in 19 out of  the 24 tissue samples and constituted 0.75% of  total cells. CRB2 was signifi-
cantly overexpressed in podocytes compared with all other cell types. Additionally, CRB2 expression was 
specific to clusters representing podocytes and PEC (Figure 5C).
Table 1. Cluster cell type and number of cells
Cluster Cluster name Abbreviation Number of cells
1 Fibroblast FIB 58
2 Podocyte POD 170
3 Myeloid cell MYL1 896
4 Myeloid cell MYL2 473
5 NK cells NKC 565
6 Endothelial cell EC-AEA 461
7 Endothelial cell, peritubular EC-PT 988
8 Glomerular capillary endothelial cell GC-EC 900
9 Vascular smooth muscle cell and mesangial vSMC/MC 655
10 Proximal tubule cell PT-1 891
11 Proximal tubule cell PT-2 1212
12 Proximal tubule cell PT-3 987
13 Proximal tubule cell PT-4 813
14 Proximal tubule cell PT-5 891
15 Proximal tubule cell PT-6 1412
16 Proximal tubule cell PT-7 525
17 Intercalated β cell IC-B 174
18 Intercalated α cell IC-A 977
19 Transitioning principal cell/intercalated cell tPC-IC 165
20 Thick ascending limb cell TAL 1343
21 Distal convoluted tubule cell DCT 901
22 Connecting tubule CNT 451
23 B cell B cell 141
24 Cytotoxic T cell T-CYT 1091
25 T cell, activated T Cell 1095
26 T cell, memory T-CYT-MEM 898
27 Principal cell PC 1164
28 Cortical connecting tubule principal cell PC-CNT 414
29 Ascending thin limb cell ATL 656
30 Parietal epithelial cell/loop of Henle PEC 158
31 Descending thin limb cell DTL 743
    Total 22268 cells
Distribution of single cells isolated from tissue samples in 31 clusters and associated cell types.
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Cluster 9 contained cells with known markers of smooth muscle cells, ACTA2, and TAGLN, consistent 
with vascular smooth muscle cells and mesangial cells (VSMC/MC). The specific antibody staining of ITGA8 
and SYNPO2 in the HPA authenticated the presence of MCs in this cluster (Supplemental Figure 2).
Multiple distinct immune cell types were observed in the scRNAseq data of  the reference tissues. 
Seven distinct immune clusters were identified: myeloid cells (clusters 3 and 4), NK cell (NKC) (cluster 
5), B cell (cluster 23), cytotoxic T cell (T-CYT) (cluster 24), activated T cell (T-ACT) (cluster 25), and 
T memory cell (T-MEM) (cluster 26).
Cluster 1 — the smallest cluster, comprising only 58 cells — was identified as a fibroblast cluster 
based on its top markers, including decorin (DCN), collagen type 1 α 2 (COL1A2), and lumican (LMN).
Based on the known endothelial marker CD34, three endothelial clusters were identified (clusters 
6, 7, and 8); specific markers for these 3 clusters include SERPINE2 (cluster 6), PLVAP (cluster 7), 
and EHD3 (cluster 8) (Figure 3B). These 3 endothelial clusters were the focus of  further evaluation of  
underlying biological processes and their relationship to disease progression.
Figure 4. UMAP plot showing the distribution of the single cells from the 24 samples used in the study. (A) UMAP plot showing the distribution of the 
cells in the 31 clusters resulted from the unsupervised clustering of the scRNAseq data from tumor-nephrectomy, surveillance, and preperfusion biopsies. 
(B) UMAP plot of the 14,744 cells from the 16 tumor-nephrectomy samples. (C) UMAP plot of the 4690 cells from the 5 surveillance transplant biopsy 
samples. (D) UMAP plot of the 2834 cells from the 3 preperfusion biopsy samples.
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Figure 5. Cell type markers of clusters 19 and 30. (A) Violin plots of PC and IC cell markers: FXYD4 expression in PC (cluster 27); SLC26A7 in ICA 
cells (cluster 18); SLC4A9 in ICB (cluster 17); and all 3 in transitional PC-IC cells (cluster 19). (B) tSNE plot of the 2 subclusters of cluster 30; dot plot 
of relative expression levels and HPA antibody staining of parietal endothelial cells (CRB2, CLDN1, and WT1 in subcluster 0) and LOH cell markers 
(SPP1, TACSTD2, and SLC128A1 in subcluster 1). (C) Violin plot shows the specific NPHS2 expression in cluster 2 (podocytes). HPA antibody staining 
of NPHS2 confirms its specific expression in podocytes. Violin plot of CRB2 expression shows that this gene is expressed in clusters 2 and 30. HPA 
antibody staining of CRB2 shows that it is expressed in podocytes and parietal epithelial cells. The HPA antibody stainings are from normal human 
kidneys, and figures indicate scale of 20 μm; additional details in Supplemental Figure 6). PC, principal cells; IC, intercalated; PEC, parietal epithelial 
cells; LOH, Loop of Henle; HPA, Human Protein Atlas.
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Comparative assessment of  adult kidney single cell data. We used independently generated kidney single 
cell or single nucleus datasets to assess the cell type distribution and coverage of  the scRNAseq data 
from adult kidney tissue samples. To compare the average gene expression of  genes in major cell types 
identified in published developing kidney tissue data (10) with that of  the cell types in our adult kidney 
scRNAseq data, heatmaps using Pearson’s correlation values were generated. Positive correlation of  
average expression levels between the corresponding cell types in the 2 data sets — especially between 
the podocytes, distal tubular, collecting duct, endothelial, stromal, and immune cells — were observed 
(Figure 6A). In addition, we similarly compared our data with published adult human kidney snRNA-
seq dataset (19). Average transcript expression of  the major cell types in the 2 data sets had correlation 
values greater than 0.7 (Figure 6B).
Validation of  endothelial cell types. Unlike bulk mRNA analysis, the single cell technology was success-
ful in characterizing multiple endothelial cell clusters. Confirming the distinct cellular identities of  these 
clusters, we demonstrated the expression of  1 distinct marker for each of  the 3 endothelial cell clusters, 
clusters 6–8 (Figure 7A), using in situ hybridization (ISH; Figure 7B). As predicted from the scRNAseq 
analysis, the ISH signal for SOST was found to be specific to glomerular endothelial cells (GECs) (cluster 
6); PLVAP probes hybridized to peritubular capillary endothelial cells (cluster 7) and SERPINE2 were 
specifically expressed in arteriolar endothelial cells (cluster 8). We were also able to validate these find-
ings by clustering mouse kidney scRNAseq data available at NCBI, Gene Expression Omnibus (GEO) 
dataset (GSE107585) (14) and identifying 3 similar endothelial cell subclusters (Figure 7C). Further-
more, the top markers in the 3 human kidney endothelial clusters also marked peritubular capillary endo-
thelial, glomerular endothelial, and arteriolar endothelial cells in murine scRNAseq data (Figure 7D).
Figure 6. Validation of cell cluster assignment. (A) Heatmap of correlation between the average expression of genes in cell 
types identified in human developing kidney and adult kidney scRNASeq data (columns, developing kidney; rows, adult kid-
ney). (B) Heatmap showing correlation between the average expression of genes in cell types identified in scRNAseq (rows) 
and snRNASeq (columns) analyses. Row-wise Z-score scaling of gene expression was used for heatmap visualization.
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Figure 7. Endothelial cell types. (A) Violin plots with cluster-specific 
expression of SERPINE2 in arteriolar endothelial cells (cluster 6), 
PLVAP in peritubular endothelial cells (cluster 7), and EHD3 in glomer-
ular endothelial cells (cluster 8). (B) Validation using ISH for the spe-
cific expression of SOST, PLVAP, and SERPINE2 in glomerular endo-
thelial, peritubular capillary endothelial, and arteriolar endothelial 
cells, respectively. SERPINE2 and SOST images have magnification 
of 400×. Scale bars: 20 μm. The PVLAP image has magnification of 
200×. Scale bar: 50 μm. (C) UMAP plot showing the clusters from the 
integrated analysis of human and mouse endothelial cells. Unsuper-
vised clustering using Seurat R package at a resolution of 0.1 resulted 
in 3 distinct clusters. Cells from both human and mouse scRNAseq 
data were found in the 3 clusters. (D) Heatmap of the top 5 markers 
for each of the 3 clusters from the integrated analysis of human and 
mouse endothelial cells. Differential gene expression analyses, to 
identify cell type–specific genes, were performed using the nonpara-
metric Wilcoxon rank sum test. The cell type–specific genes that 
were differentially expressed with FDR < 0.05 were considered.
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Integrative analysis of  single cell endothelial marker with bulk mRNA identifies a distinct FSGS subgroup 
with activated GECs. Endothelial dysfunction has been shown to contribute to the development and pro-
gression of  kidney diseases (23). Focusing on the 3 endothelial cell clusters in our data (Figure 8A), we 
identified 26 genes selectively expressed in all 3 endothelial clusters and 78 genes specific to GECs (Fig-
ure 8A, yellow). The set of  GEC-specific genes were used to derive an aggregate GEC score to extract 
the differential regulation of  these transcripts in bulk kidney biopsy transcriptomic data sets. The GEC 
scores were determined for the glomerular transcripts across 10 glomerular kidney diseases studied in 
the European Renal cDNA Bank (ERCB, Figure 8B) and the NEPTUNE (Figure 8C) cohorts. In both 
cohorts, the highest average and median GEC scores were observed in patients with focal segmental 
glomerulosclerosis (FSGS), and GEC scores were significantly higher in glomerular disease samples 
compared with biopsies from living kidney donors (P < 0.005) (Figure 8, B and C). Interestingly, FSGS 
patients with exposure to immunosuppressive treatment showed significantly lower GEC scores com-
pared with treatment naive patients at time of  biopsy, consistent with an acute inflammatory nature of  
the endothelial score signature (Figure 8C). Given the functional heterogeneity of  patients with FSGS, 
we evaluated the GEC transcripts for their ability to distinguish groups within FSGS using bulk RNAseq 
profiles available from NEPTUNE. Two distinct clusters (Figure 9A), group 1 (40 patients; median GEC 
score, –0.26) and group 2 (28 patients; median GEC score, 0.37) were identified. In a genome-wide com-
parison, we found 3745 genes significantly differentially expressed (FDR < 0.05) between group 1 and 
group 2 (top 100 differentially expressed genes shown in Supplemental Table 3).
For the top 100 overexpressed genes between groups 1 and 2, we were able to identify 3 significant 
kidney-specific functional modules: Angiogenesis, extracellular matrix, and cell cycle (Figure 9B). An 
interaction network generated using STRING (24) for the same top 100 genes is shown in Figure 9C. This 
network included direct interactions between the top endothelial markers, including NRP1, TEK, and 
KDR, with FN1, a known marker implicated in glomerulosclerosis. Additionally, extracellular matrix– 
and mitotic cycle–associated proteins were enriched in the interaction network (Figure 9C).
We used weighted gene coexpression network analysis (WGCNA), which identifies coexpression mod-
ules that encapsulate the correlation patterns among genes across samples in order to further elucidate the 
functional context of  the endothelial network contained in the 2 FSGS groups. The top 2 gene set mod-
ules that significantly correlated with the groups (1 and 2) and GEC scores (for each sample) were brown 
module, with 517 genes positively correlated with the GEC score and the groups, whereas a blue module 
with 1106 genes negatively correlated with these traits (Supplemental Figure 3A). The positively correlated 
genes were enriched for Gene Ontology (GO) biological processes, including glomerulus vasculature, Ras 
protein signaling, and type 1 IFN response. The negatively correlated genes were mainly enriched for the 
TGF-β signaling pathway (Supplemental Figure 3A). WGCNA using just patient data with no immunosup-
pressive treatment exposure at time of  biopsy from group 1 and group 2 showed the enrichment of  similar 
biological processes (Supplemental Figure 3B).
We then examined predicted upstream regulators of  the genes differentially expressed between 
group 1 and group 2. Evaluating enrichment and direction of  differential gene expression changes 
using known cause-and-effect relationships, the top upstream regulators were predicted using Ingenu-
ity Pathway Analysis (IPA). A positive activation score indicates that the upstream regulator was acti-
vated for the observed differential gene expression pattern. STAT1 and VEGF were the top 2 upstream 
regulators with high activation scores (Figure 9D).
The mechanistic network of  both STAT1 and VEGFA shown in Figure 9E identified A2M as a rele-
vant downstream target gene. A2M was also the top differentially expressed gene in FSGS samples when 
comparing group 2 with group 1, based on log counts per million (log cpm) and log fold change (logFC).
To summarize, from this multilevel integrative analysis, we identified 2 subgroups of  FSGS patients 
with distinct molecular expression patterns differentiated by the expression of  GEC genes. Multiple lines 
of  evidence implicated A2M as a downstream target differentially regulated in those FSGS subgroups.
Intrarenal A2M mRNA expression associates with FSGS disease progression. Figure 10A shows the aver-
age mRNA expression of  A2M in the 2 groups identified based on GEC scores among FSGS partici-
pants in NEPTUNE. Significantly higher A2M expression is observed in group 2 compared with group 
1. A2M IHC in normal human kidney tissue in HPA indicates robust glomerular protein staining in a 
pattern following the mRNA expression (Figure 10B). In scRNAseq A2M expression was found in the 
3 endothelial cell subtypes and VSMC/MCs in adult human kidney (Figure 10C). A2M ISH in sections 
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from reference and FSGS kidney tissue showed a pattern consistent with the endothelial and mesangial 
scRNAseq expression (Figure 10D). Replicating the NEPTUNE results, higher expression levels of  
A2M transcripts were observed in samples from patients with FSGS and diabetic nephropathy (DN) in 
the ERCB cohort compared with living donors (Figure 11A and Table 2). Finally, high A2M mRNA 
expression at the time of  initial biopsy were associated with poor prognosis, as evidenced by the longer 
time to reach complete remission of  proteinuria in NEPTUNE study participants (Figure 11B).
Discussion
We successfully generated a reference kidney single cell expression atlas with 22,268 cells derived from 
31 distinct kidney cell types. The cell clusters covered the entire spectrum of  kidney cell types found 
Figure 8. Analysis of glomerular 
endothelial marker genes. (A) Venn 
diagram intersect of endothelial-specific 
clusters from scRNAseq data highlighted 
30 genes specific to all 3 endothelial 
clusters. (B and C) Glomerular endothelial 
cell (GEC) scores, derived based on 78 
genes selective for glomerular endothe-
lial cells (yellow), were calculated for 
patients and compared across the kidney 
disease spectrum in the European renal 
cDNA bank cohort (ERCB) (B) and the 
NEPTUNE cohort (C). GEC scores were 
elevated in disease groups compared 
with those of living donors. The GEC 
scores in FSGS patients with exposure 
to immunosuppressants prior to time of 
biopsy was substantially lower compared 
with those with no prior exposure. AAV, 
ANCA-associated vasculitis; DN, diabetic 
nephropathy; FSGS, focal segmental 
glomerulosclerosis; HTN, hypertensive 
nephropathy; IgAN, IgA nephropathy; 
MCD, minimal change disease; MN-MGN, 
membranous glomerulonephritis; SLE, 
systemic lupus erythematosus; TMD, 
thin basement membrane disease; LD, 
living donor; TNx, unaffected parts of 
tumor-nephrectomy.
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along the nephron, as well as resident immune cells. Clustering of  the single cell data from a single 
sample type may miss a rare cell type, like podocytes, due to lack of  power based on number of  cells. 
However, the combined analysis of  the 22,268 cells enabled the detection of  a distinct podocyte cell 
cluster. Additionally, generating single cell transcriptomics data from adult human kidney tissue can 
be challenging due to the rapid decline of  cell viability upon tissue dissociation (17). In this study, we 
were able to analyze single cell transcriptomic data from 16 tumor-nephrectomies, 5 surveillance biop-
sies derived from transplant patients with normal kidney function and histology, and 3 preperfusion 
living donor biopsy samples and assign cells to distinct clusters without significant confounders due 
to the tissue source. Furthermore, by integrating the cell type–specific information of  GECs with bulk 
Figure 9. Integrated analysis of scRNAseq and bulk mRNAseq data. (A) Two distinct groups from the hierarchical clustering of the 78 glomerular endo-
thelial cell defining mRNA transcripts in isolated glomeruli of FSGS biopsy samples from the NEPTUNE cohort. (B) Kidney-specific functional module gene 
interaction network (https://hb.flatironinstitute.org). The figure shows the 3 significant functional modules and their interactions. (C) Protein interaction 
network generated using STRING for the top 100 genes that were substantially overexpressed in group 2 versus group 1. (D) Top upstream regulators pre-
dicted by IPA. The bar plots show the activation scores predicted by IPA for the top 5 upstream regulators (P < 0.05 by Fisher’s exact test). (E) The regulatory 
interaction of the top 2 regulators, VEGF growth factor, and STAT1 show A2M as a downstream target. FSGS, focal segmental glomerulosclerosis.
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mRNA data, we were able to identify 2 distinct groups of  FSGS patients, with GEC activation being 
most prominent in immunosuppressive naive patients.
The need to generate single cell suspensions from complex tissues can introduce a selection bias 
by the isolation procedure. In KPMP parallel strategies of  cell-level analyses are pursued and allow 
direct comparison between the different technologies. Comparison of  our kidney single cell data with 
published single nucleus data (19) show a significant overlap with robust cell-to-cell correlation but 
also are complementary, with certain cell types more enriched in one compared with the other technol-
ogy. For example, enrichment of  immune cells is observed in scRNAseq compared with snRNAseq, 
Figure 10. α-2-Macroglobulin 
(A2M) expression. (A) Box plot 
showing average glomerular 
RNAseq read count of A2M 
transcripts in samples from the 
GEC group 1 and group 2. (B) 
Human Protein Atlas antibody 
staining of A2M in normal 
human kidney. Scale bar: 50 
μm. (Supplemental Figure 6 
contains specific information on 
HPA immunostaining of A2M). 
(C) Violin plot showing the cell 
type scRNAseq expression of 
A2M transcripts in adult human 
kidney. (D) In situ hybridization 
fluorescence images showing 
the glomerular signal of A2M 
probes in 2 unaffected parts of 
tumor-nephrectomy (left panel) 
and FSGS (right panel) kidney 
tissue sections. Glomeruli are 
encircled by thin white lines. 
The images are at 200× magni-
fication. Scale bar: 50 μm.
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providing a strong rationale to study the adult human kidney at the single cell level for a thorough 
understanding of  the kidney transcriptome.
One of  the key features in our study is the integration of  the single cell data, with glomerular 
mRNA biopsy gene expression data dissecting the contribution of  specific cell types to the disease state. 
In this study, we focused on endothelial cell phenotypes in the kidney, given their known involvement, 
and the limited mechanistic elucidation of  their role in human glomerular disease pathophyisiology, 
thus far. We observed 3 distinct endothelial cell types across all 3 reference tissue sources and confirmed 
the same cluster pattern by reanalyzing a published murine study (14, 25) with the recent study of  
murine kidney by Dumas et al., showing extensive renal endothelial cell phenotypic heterogeneity (25).
The scRNAseq endothelial subtype–specific gene sets enabled the development of  a GEC score. The 
GEC score was subsequently applied to bulk gene expression data sets from microdissected glomeruli 
(Glom) obtained from patients with a wide spectrum of  glomerular diseases. We not only could observe dif-
ferential regulation of  the GEC markers across diseases, but we could also identify 2 subgroups of  patients 
with activation of  the GEC-specific genes in FSGS, a disease known for its substantial heterogeneity in 
disease initiation, treatment responsiveness, and rates of  progression (26, 27).
In the FSGS patient kidney biopsies, known endothelial marker genes NRP1, KDR, and TEK, 
encoding the receptors for growth factor ligands including VEGFA, VEGFD, ANGPT1, and ANGPT2, 
Figure 11. A2M expression in FSGS. (A) Box plot showing the expression of A2M mRNA in different kidney diseas-
es in ERCB cohort: DN, FSGS, MCD, MN, LD. (D) Kaplan-Meier curves by A2M mRNA expression levels at baseline 
biopsy for the first complete remission event in NEPTUNE FSGS patients. Two-sided Student’s t test showed that 
high A2M mRNA expression at the time of initial biopsy was associated with poor prognosis, as evidenced by the 
longer time to reach complete remission of proteinuria in NEPTUNE study participants (P < 0.02). DN, diabet-
ic nephropathy; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN, membranous 
nephropathy; and LD, living donor.
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were overexpressed in FSGS group 2 compared with group 1 (Supplemental Figure 4). The single cell 
analysis enabled us to identify the cell type–specific expression of  these ligands and receptors. Sup-
plemental Figure 4A illustrates the potential cell-to-cell interactions between the endothelial cells and 
podocytes, fibroblast, and MCs.
The endothelial cell–driven gene signatures juxtapose patients with an inflammatory GEC acti-
vation state from those with profibrotic glomerular transcriptional signatures (28). The 2 FSGS groups 
were characterized by distinct expression signatures with group-specific functional enrichments. Both kid-
ney-specific functional module analysis and the STRING interaction network illustrated similar functional 
enrichments. Extracellular matrix functional processes, endothelial development, and cell division were 
significantly enriched for the genes that were overexpressed between group 2 and group 1. The functional 
enrichment of  the genes in the WGCNA module showed glomerular vasculature development, type 1 IFN, 
and RAS protein signaling pathways as enriched in group 2 compared with group 1 (Supplemental Figure 
3A). TGF-β signaling response genes, which have an established profibrotic role in FSGS pathology, were 
higher in group 1 compared with group 2 (29).
The enrichment of  type 1 IFN signaling in group 2 compared with group 1 and the identification of  
STAT1 as the top upstream regulator for the differentially expressed genes in this group is consistent with 
established STAT1 activation by IFNs (30, 31). Tao et al. have described activation of  the JAK/STAT 
signaling pathway in FSGS in the NEPTUNE cohort (32), with higher STAT1 transcriptional activity 
scores and elevated levels of  phosphorylated STAT1 in glomerular and tubular compartments from FSGS 
patients. Together, these findings suggest that type 1 IFN–mediated STAT1 activation could be a key mech-
anism involved in glomerular disease progression for group 2 patients with endothelial cell activation. In 
a phase II clinical trial for patients with diabetic kidney disease, treatment with a JAK/JAK2 inhibitor 
resulted in a reduction in albuminuria (4) and was well tolerated, suggesting that this mechanism may also 
be amenable to therapeutic intervention in patients with FSGS. Intriguingly, the GEC score was highest in 
immunosuppressive treatment–naive NEPTUNE participants and significantly lower in patients with ste-
roid and/or second-line immunosuppression at time of  biopsy (Figure 8C). This argues not only for a high 
inflammatory state of  the endothelium in a substantial subset of  untreated FSGS patients (Supplemental 
Figure 3B), but it is also consistent with the ability of  immunosuppressive treatments to rapidly impact the 
GEC activation in FSGS. Crosstalk between endothelial cells with MCs and podocytes supports a highly 
dynamic role of  the glomerular endothelium in FSGS (Supplemental Figure 4).
Analysis of the differences in the gene expression of the 2 GEC-defined groups pointed to A2M as a down-
stream mediator linked to the FSGS heterogeneity. Upstream regulator analysis predicted A2M as a target 
gene of STAT1. This observation is further supported by Satoh and Tabunoki (33), who identified A2M as a 
target gene for the STAT1 transcription factor in their ChIP-seq analysis. A2M protein is a known marker of  
glomerular permselectivity, a property of the glomerular capillary wall that serves to exclude macromolecules 
from the urinary space. The ratio of urine A2M protein to albumin has been reported as a predictor of steroid 
response since as early as 1964 (34), with filtered A2M in the urine as an indicator of severe loss of glomerular 
permselectivity. The limited immunohistochemical staining of A2M in kidney biopsies have, thus far, been 
viewed as systemic and incidental to loss of glomerular permselectivity, rather than the consequence of intra-
renal A2M synthesis (35). Our mRNA gene expression data sets from scRNAseq, microdissected glomerular 
RNAseq, and ISH argue for an intrinsic intrarenal regulation of A2M in glomerular disease (Figure 10D). 
A2M is a nonspecific protease inhibitor able to impact the function of a wide range of proteins (36). Relevant 
in a glomerular context is the ability of A2M to inhibit matrix-degrading proteases, including MMPs (37). Inhi-
bition of MMP is one mechanism leading to the glomerular matrix accumulation characteristic of FSGS. The 
Table 2. A2M expression in different kidney diseases in the ERCB cohort
ANOVA results FSGS MN MCD DN
Group A2M LD 6 × 10–7 0.05 0.04 0
P value 0.006 DN 0.83 0.02 0.11 NA
F value 7.714 MCD 0.4 0.99 NA 0.1
Two-way ANOVA indicates significant difference (P < 0.001) in A2M transcript levels in FSGS and DN patients compared with LD. DN, diabetic nephropathy; 
FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN, membranous nephropathy; and LD, living donor.
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STRING protein interaction and kidney-specific functional module analyses in the glomerular NEPTUNE 
data sets indicate a close link between A2M and glomerular matrix changes in the FSGS population studied.
Podocyte injury is the earliest observed morphological feature of  FSGS (26, 38). A2M is an effective 
inhibitor of  activated protein C (aPC) (39), with recent data indicating aPC as protective against apoptosis 
of  podocytes in DN (40). Thus, inhibition of  aPC by A2M may block the protective role of  aPC. In addi-
tion, repression of  aPC is known to enhance thrombin generation (41), and Kerlin and colleagues recently 
have shown that thrombin injures podocytes (42). A2M-mediated inhibition of  aPC-mediated podocyte 
protection may simultaneously enhance thrombin-mediated podocyte injury.
There are several limitations to be considered with the described study. Multiple tissue sources were 
used to represent the normal tissue state of  the kidney. While each of  these sources has its specific lim-
itations, contribution of  all 3 tissue sources to the cellular clusters identified argues for the robustness 
of  the cellular differentiation reported.
One intrinsic limitation of  single cell studies is the need to generate single cell suspension, which may 
cause selective loss of  some cell populations (17). For example, podocytes are highly sensitive to tissue 
dissociation processes. However, the proportion of  podocytes recovered by our protocol was aligned with 
the abundance of  these cells in adult kidneys reported by others (20, 43). The resolution used in the unsu-
pervised clustering step could have resulted in the overclustering of  proximal cells to 7 clusters rather than 
to the known 3 segments, namely S1, S2, and S3. However, a lower resolution would have missed the iden-
tification of  other major kidney cell types. Comparison with the snRNAseq data indicates a good overall 
agreement between clusters and cluster-associated transcripts. Further studies to systematically compare 
and integrate the different single cell technologies on the same adult human tissue are ongoing in KPMP. 
Another caveat of  this study is the impact of  tissue dissociation at 37°C. Our initial bulk mRNA analysis on 
pre- and postdissociation kidney tissue indicated no effect; however, more detailed analysis is warranted to 
rule out the impact of  tissue dissociation at 37°C (Supplemental Figure 5, A–C).
In this study, we generated a comprehensive single cell transcriptome of  the adult human kidney and 
identified known and potentially novel cell type–specific markers, along with transient cell types between 
renal segments. Our scRNAseq-driven endothelial cell characterization in FSGS Glom revealed potential-
ly novel molecular heterogeneity within patients with FSGS. We identified 2 distinct FSGS groups with 
significant differences in the intrarenal A2M gene expression levels. The group with the higher A2M gene 
expression associated with poor prognosis. As molecular pathways linked to FSGS are targeted by several 
emerging therapeutics, this integrative analysis provides avenues for investigation whereby not only insights 
into differences in normal and diseased adult human kidneys can be gathered, but such explorations can 
also serve as frameworks for precision medicine in order to identify the appropriate drug for a specific 
patient diagnosed with a glomerular disease.
Methods
Human samples. For generating the single cell transcriptome, we processed 24 CryoStor preserved human 
kidney samples: 16 tumor-nephrectomy, 5 human allograft kidney transplant surveillance, and 3 preper-
fusion transplant biopsy samples. Ten of  the 16 tumor-nephrectomy samples were processed at the Broad 
Institute, and all the remaining samples were processed at the University of  Michigan. The surveillance 
biopsies were obtained from patients at 3–6 months after transplant; all 5 biopsy samples were confirmed 
as histologically normal. Additionally, 3 preperfusion biopsies procured from donor kidneys before trans-
plant were used as most representative of  normal kidney tissue. Only small quantities (2–3 mg) of  the 
biopsy samples were used for the scRNAseq procedure.
As part of  the Accelerating Medicines Partnerships lupus network Pathway Exploration and Anal-
ysis in Renal disease (AMP-PEARL) network, we have developed and optimized protocols for kidney 
biopsy sample acquisition in distributed research networks for dissociation of  single cell suspension and 
subsequent RNAseq studies (15). We modified the protocol published by the AMP-PEARL network to 
increase kidney epithelial cell yield. Briefly, kidney biospecimen were placed in 1 mL HypoThermosol 
(Stemcell Technologies) and immediately transferred to the laboratory and cryopreserved in DMSO con-
taining CryoStor CS 10 (Stemcell Technologies) solution for long-term storage in liquid nitrogen (Figure 1).
Single cell isolation. For tissue dissociation, samples were quickly thawed in a 37°C water bath for 1 
minute, transferred to a small dish containing 1 mL DMEM/F12 medium (with L-Glutamine, HEPES, 
and high glucose) supplemented with 10% heat-inactivated FBS, and incubated for 10 minutes at room 
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temperature. Tissue/biopsy samples were cut into 1-mm3 pieces to increase the surface area before they 
were transferred to a 1.5-mL tube containing 500 μL DMEM/F12 digestion media, which contained 125 
ng Liberase TL (MilliporeSigma) enzyme. Samples were incubated on an orbital shaker (500 rpm) for 12 
minutes at 37°C with a mild trituration step using a wide-bore 1000 μL tip applied after 6 minutes. Diges-
tion was stopped by adding 500 μL DMEM/F12 medium containing 10% FBS and incubated at room 
temperature for 1 minute. The cell suspension was then filtered through a 30-μm strainer (Milteny Biotec) 
into a 15-mL conical tube. Remaining solid tissue was passed through the nylon mesh using the rubber end 
of  a 3-mL syringe pestle, and the filter was washed with 10-mL DMEM/F12/10%FBS medium. Cells were 
pelleted by centrifugation for 10 minutes at 200 g at 4°C. The supernatant was immediately, completely 
removed by vacuum suction using a glass Pasteur pipet. The cell pellet was then gently resuspended in 55 
μL DMEM/F12/10%FBS medium, and cell viability was analyzed with a Countess II FL automated cell 
counter exploiting the trypan blue dye exclusion method.
10× Genomics and Next Generation Sequencing (NGS) of  single cell mRNA. Single cell samples were imme-
diately transferred to the University of  Michigan Sequencing Core facility. About 10,000 viable cells in up 
to 46 μL DMEM/F12/10%FBS per sample were added to each channel of  a chip on the droplet-based 
high-throughput 10× Genomics Chromium platform allowing cell lysis, individual cell barcoding, and 
reverse RNA transcription. We used the 10× Single Cell 3’ GEX – version 2 chemistry for all tumor-ne-
phrectomy samples and the enhanced 10× Single Cell 3’ GEX – version 3.1 for the more recently pro-
cessed transplant surveillance biopsies and preperfusion biopsies. Single cell library preparation was exe-
cuted by the core facility and included emulsion breakage, PCR amplification, cDNA fragmentation, oligo 
adapter, and Illumina sample index addition. Libraries have been pooled and sequenced on an Illumina 
HiSeq4000 platform as asymmetric paired end runs (26 × 115 bases) with a median of  100 million raw 
sequencing reads per sample. The output from the sequencer was first processed by CellRanger, the pro-
prietary 10× Chromium single cell gene expression analysis software (https://support.10xgenomics.com/
single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger).
Tissue dissociation effect analysis. To account for the potential for genes to be induced during tissue disso-
ciation using Liberase TL at 37°C, we compared bulk gene expression RNAseq data before and after cell 
dissociation for 4 tumor-nephrectomy samples (Supplemental Figure 5A). We found a stringent correlation 
between pre- and postdissociation gene expression for each of  the 4 samples (Supplemental Figures 5, B 
and C). Pre- and postdissociation bulk mRNA analysis show that the short duration of  12 minutes of  disso-
ciation using Liberase TL did not have a significant impact downstream biological processes.
Data analysis of  single cell data. Data analyses were performed on the CellRanger output data files 
using Seurat 3 R package (https://cran.r-project.org/web/packages/Seurat/index.html). As a quality 
control step, cells with less than 500 genes per cell were filtered out. The percentage of  mitochondrial 
gene read content has emerged as a quality measure for the cell viability in single cell studies. A high 
percentage of  mitochondrial reads indicate that the cells are less viable, indicative of  cytoplasmic mRNA 
loss due to the degradation of  plasma membrane during the dissociation process. For the tumor-ne-
phrectomy data generated applying the Chromium Next GEM Single Cell 3′ GEM, Library & Gel Bead 
Kit version 2, a threshold of  < 20% mitochondrial reads per cell was used, whereas a cutoff  of  < 50% 
mitochondrial reads per cell was applied for the data from the version 3 kit. It has been observed by us 
and other groups that, for certain tissues, including kidney, 10× Genomics version 3 chemistry results 
in a higher percentage of  mitochondrial reads, irrespective of  the viability status of  the cells. This issue 
was circumvented by deeper sequencing of  the samples (200 million reads) to obtain more genes per cell. 
After the quality control step, the data from the 3 sample types (tumor-nephrectomy, surveillance biopsy, 
and preperfusion biopsy) were merged and further analyzed. Doublet formation is a concern in single 
cell technology, where 2 cell types in close proximity can be engulfed by a single droplet. The mRNA 
content and number of  genes of  doublets are comparatively higher than mRNA content and number 
of  genes of  single cells. In order to reduce doublets or multiplets from the analysis, we used a cutoff  of  
> 500 and < 5000 genes per cell. However, in certain cell types (for example, in the cells transitioning 
between 2 cell types), the mRNA content can be higher than other cell types (cluster 19, in this study).
The downstream analysis steps included SCTransform, dimensionality reduction principal compo-
nent analysis (PCA) and UMAP (44), standard unsupervised clustering, and the discovery of  differentially 
expressed cell type–specific markers (45). We used the SCTransform functionality embedded in Seurat R 
package for normalization and scaling of  UMI and mitochondrial content. In addition, we included the 
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batch information as a variable in the SCTransform to scale out the differences between the batches. For the 
unsupervised clustering, we chose 1.75 as the resolution parameter. Differential gene expression analyses, to 
identify cell type–specific genes, were performed using the nonparametric Wilcoxon rank sum test. Harmo-
ny, a R package, was used to integrate single cell datasets before the unsupervised clustering (46).
For cell type annotation, we used publicly available resources, including Kidney Interactive Transcrip-
tome (http://humphreyslab.com/SingleCell/), HPA (https://www.proteinatlas.org), the Epithelial Sys-
tems Biology Laboratory (ESBL) (https://hpcwebapps.cit.nih.gov/ESBL/Database/), scRNAseq data 
(19), and Immgen (https://www.immgen.org/).
Bulk mRNA profiling from patients with kidney disease. Total RNA was isolated from microdissected kid-
ney Glom of  biopsy samples from the ERCB cohort and from the NEPTUNE cohort using well-estab-
lished protocols that demonstrate enrichment for abundance of  glomerular mRNAs (47, 48). Microarray 
profiles were generated on glomerular samples as previously described (49) and were deposited into GEO 
under accession numbers GSE104948 (ERCB) and GSE104066 (NEPTUNE). Bulk glomerular RNAseq 
expression data were obtained for 74 participants with biopsy-proven FSGS enrolled in the NEPTUNE 
study. Briefly, mRNA samples were prepared using the Illumina TruSeq mRNA Sample Prep v2 kit. Multi-
plex amplification was used to prepare cDNA with a paired-end read length of  100 bases using an Illumina 
HiSeq2000. RNAseq was performed by the University of  Michigan Advanced Genomics Core (https://
brcf.medicine.umich.edu/cores/advanced-genomics/). Quality of  the sequencing data was assessed using 
the FastQC tool (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Read counts were extract-
ed from the fastq files using HTSeq (version 0.11). The objectives and study design of  NEPTUNE can be 
found in the clinicaltrials.gov database under NCT1209000 (50).
Development of  the GEC transcription score. Aggregate GEC scores were generated in samples profiled on 
microarrays from patients across the kidney disease spectrum who were part of  the ERCB and NEPTUNE 
cohorts. We established a glomerular GEC score from 78 glomerular endothelial marker genes identified 
from single cell data using previously described methods (12, 49). Genes expressed on glomerular microar-
ray profiles from ERCB (60 of  78 genes) and NEPTUNE (77 of  78 genes) were Z-transformed; then, the 
average Z-score per disease group was used for comparison among diseases.
WGCNA of  bulk mRNA data. Gene set modules were generated by WGCNA (51) of  the top 5000 
variable genes between the groups 1 and 2 identified through hierarchical clustering of  bulk mRNA 
expression profiles of  the 74 FSGS patients. Enriched GO biological processes were identified for the 
coexpressed gene sets.
Kidney-specific functional modules. Module detection was performed using a kidney tissue–specific gene 
functional network (52, 53). We consider the subgraph of  the kidney-specific network consisting of  the top 
100 genes significantly overexpressed in group 2 FSGS patients relative to group 1 FSGS patients, as well as 
all edges between them. Four of  the top genes were not present in the kidney-specific functional network, 
leaving a network of  96 genes. For each pair of  these genes, we then counted the number of  shared neigh-
bors among the top k edges in the subgraph incident to each gene, and we chose the 5% of  pairs with the 
most shared neighbors as edges in a shared k-nearest neighbors (sKNN) graph. (Here, k is set to 20% of  
the number of  genes). We then performed community clustering using the Louvain algorithm to identify 
modules in the sKNN graph. Community clustering was repeated 100 times, and a comembership score 
was computed for each pair of  genes. The comembership score was equal to the fraction of  runs in which 
the gene pair was assigned to the same module. To produce output modules, community clustering was 
performed on the graph with edges between each pair of  genes with a comembership score of  at least 90%.
Validation of  endothelial cell types using ISH. In situ detection of sclerostin (SOST, RNAscope probe_Hs-SOST, 
Advanced Cell Diagnostics [ACD], catalog 452941), plasmalemma vesicle associated protein (PVLAP, RNA-
scope probe_Hs-PLVAP, ACD, catalog 437461), serpin family E member 2 (SERPINE2, RNAscope probe_
Hs-SERPINE2, ACD, catalog 412661) and α-2-macroglobulin (A2M, RNAscope probe_Hs-A2M-C2, ACD, 
catalog 532501-C2) mRNA transcripts using the RNAscope kit (Advanced Cell Diagnostics) were performed 
according to the manufacturer’s protocol by kidney pathologists able to identify cell types in kidney tissue. Sec-
tions (3 μm) sections of deidentified human kidney tissue were cut from formalin-fixed, paraffin-embedded 
(FFPE) blocks supplied by the University of Michigan Tissue Procurement Service. Housekeeping gene pep-
tidylprolyl isomerase B (PPIB) was used as an internal, mRNA control; if  the PPIB score was 0, the sample 
was regarded as not available for gene expression. A horseradish peroxidase–based signal amplification system 
(RNAscope 2.0 HD Detection Kit-Brown, ACD, catalog 310035) was used for hybridization to the target probes, 
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followed by color development with DAB, and the slides were counter-stained with hematoxylin (RICCA chem-
ical company, catalog 3535-16). Positive staining was determined by brown punctate dots in the cytoplasm.
Data sharing. The gene matrix files from the scRNAseq data and the raw read counts from the bulk 
mRNA data used in the above analyses are uploaded to NCBI GEO database under accession number 
GSE140989. Data can also be viewed at http://nephrocell.miktmc.org. The single cell data are also avail-
able at the KPMP Atlas data repository (https://atlas.kpmp.org/repository).
Statistics. The workflow of  our integrative analysis of  single cell and bulk mRNA is described in Figure 
1. EdgeR R package (54) was used for genome-wide differential gene expression analysis between the FSGS 
subgroups resulting from the hierarchical clustering of  GEC type gene expression. Model-based normaliza-
tion function embedded in the edgeR adjusted for the sequencing depth and RNA composition differences 
between the samples. Next, an empirical Bayes strategy for squeezing the tagwise dispersions toward a 
global dispersion trend or toward a common dispersion value was applied. After negative binomial models 
were fitted and dispersion estimates were obtained, testing procedures for determining differential expres-
sion using the exact test was performed. We considered only the genes that were differentially expressed 
with an adjusted P < 0.05 (54). Association between the significantly differentially expressed genes with 
clinical parameters, including time to complete remission of  proteinuria, were performed using STATA, 
v12.1 with 2-tailed Student’s t tests of  hypotheses and P < 0.05 as the criterion for statistical significance. 
Comparison of  upstream regulators related to differentially regulated genes were explored using IPA Soft-
ware Suite (https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/).
Study approval. All samples used in this study were obtained with patient consent and with the approval of  
IRBs of  participating institutions, described below. The KPMP study is reviewed and approved through cen-
tral IRB process at The Human Research Protection Office and Washington University in St. Louis (IRB no. 
201902013). Transplant biopsies were obtained after review and approval of  the Transplant Transcriptomic 
Atlas study, HUM00150968, by the University of  Michigan IRBMED. NEPTUNE data were obtained based 
on the multisite, central IRB approval for the study, HUM00158219, by the University of  Michigan IRBMED.
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